BI LITI NOAM LITI Teva asked the U.S. Patent and Trademark Office to consider reissuing the '808 patent that was invalidated in the Copaxone litigation against Sandoz, Momenta, Mylan and Natco. Teva has submitted new claims, amending the indefinite language objected to by the Federal Circuit. If the patent authorities concur, the reissue will have the same September 2015 expiry as the original '808 patent. Teva can then file new litigation against generic challengers.